Reported healthcare-seeking of loiasis patients and estimation of the associated monetary burden in Gabon: Data from a cross-sectional survey.

Autor: Luzia Veletzky, Veronika Schlicker, Jennifer Hergeth, Daniel R Stelzl, Rella Zoleko Manego, Ghyslain Mombo-Ngoma, Kirsten Alexandra Eberhardt, Matthew B B McCall, Ayôla A Adegnika, Bertrand Lell, Benjamin Mordmüller, Scherif Adegnika, Michael Ramharter, Christine Budke

Publikováno v: PLoS Neglected Tropical Diseases, Vol 18, Iss 8, p e0012389 (2024)

BackgroundLoiasis is a disease of relevance in endemic populations and there has been advocacy for its inclusion on the World Health Organization's neglected tropical diseases list. As loiasis-related healthcare-seeking behaviors and related costs ar

Externí odkaz: https://doaj.org/article/dee28f6a84784a049ea41e056b21e10c

Analysis of diagnostic test outcomes in a large loiasis cohort from an endemic region: Serological tests are often false negative in hyper-microfilaremic infections.

Autor: Luzia Veletzky, Kirsten Alexandra Eberhardt, Jennifer Hergeth, Daniel Robert Stelzl, Rella Zoleko Manego, Ruth Kreuzmair, Gerrit Burger, Johannes Mischlinger, Matthew B B McCall, Ghyslain Mombo-Ngoma, Ayôla Akim Adegnika, Selidji Todagbe Agnandji, Pierre Blaise Matsiegui, Bertrand Lell, Peter Kremsner, Benjamin Mordmüller, Dennis Tappe, Michael Ramharter

Publikováno v: PLoS Neglected Tropical Diseases, Vol 18, Iss 3, p e0012054 (2024)

BackgroundThe parasitic disease loiasis is associated with significant morbidity and mortality. Individuals with hyper-microfilaremia (greater than 20,000 microfilariae per mL of blood) may suffer from serious treatment-related or spontaneous adverse

Externí odkaz: https://doaj.org/article/08aa666e4d2a4112835931131aac9dc3

Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial.

Autor: Rella Zoleko-Manego, Ruth Kreuzmair, Luzia Veletzky, Wilfrid Ndzebe-Ndoumba, Dorothea Ekoka Mbassi, Dearie G Okwu, Lia B Dimessa-Mbadinga-Weyat, Roselyne D Houtsa-Temgoua, Johannes Mischlinger, Matthew B B McCall, Peter G Kresmner, Selidji T Agnandji, Betrand Lell, Ayôla A Adegnika, Ghyslain Mombo-Ngoma, Michael Ramharter

Publikováno v: PLoS Neglected Tropical Diseases, Vol 17, Iss 8, p e0011584 (2023)

BackgroundThere is a lack of systematic evidence for strategies to control loiasis transmission in highly endemic regions. Here we assessed albendazole and ivermectin based treatment regimens to reduce Loa loa microfilaraemia in Gabon.MethodsEligible

Externí odkaz: https://doaj.org/article/d1c6fd6007b0435199d8d832a7f548b9

Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults

Autor: Saskia C van der Boor, Merel J Smit, Stijn W van Beek, Jordache Ramjith, Karina Teelen, Marga van de Vegte-Bolmer, Geert-Jan van Gemert, Peter Pickkers, Yimin Wu, Emily Locke, Shwu-Maan Lee, John Aponte, C Richter King, Ashley J Birkett, Kazutoyo Miura, Morolayo A Ayorinde, Robert W Sauerwein, Rob ter Heine, Christian F Ockenhouse, Teun Bousema, Matthijs M Jore, Matthew B B McCall

Publikováno v: Lancet Infectious Diseases, 22, 1596-1605
Lancet Infectious Diseases, 22, 11, pp. 1596-1605

Contains fulltext : 287660.pdf (Publisher’s version ) (Open Access) BACKGROUND: Malaria elimination requires interruption of the highly efficient transmission of Plasmodium parasites by mosquitoes. TB31F is a humanised monoclonal antibody that bind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6447ac72a6a077d34ada58b429987eb
https://doi.org/10.1016/s1473-3099(22)00428-5

First-in-human use of a modular capsid virus-like vaccine platform:An open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2

Autor: Merel J Smit, Adam F Sander, Maud B P A Ariaans, Cyrielle Fougeroux, Constanze Heinzel, Rolf Fendel, Meral Esen, Peter G Kremsner, Rob ter Heine, Heiman F Wertheim, Manja Idorn, Søren Riis Paludan, Alexander P Underwood, Alekxander Binderup, Santseharay Ramirez, Jens Bukh, Max Soegaard, Sayit M Erdogan, Tobias Gustavsson, Stine Clemmensen, Thor G Theander, Ali Salanti, Mette Hamborg, Willem A de Jongh, Matthew B B McCall, Morten A Nielsen, Benjamin G Mordmüller, Robert Dagil, Louise Goksøyr, Thomas M Hulen, Christoph Janitzek, Daniel S Jensen, Sune Justesen, Paul K Khalifé, Andrea Kreidenweiss, Telma Lança, Olivia Lie-Andersen, Karina Teelen, Elena Vidal-Calvo

Publikováno v: Smit, M J & COUGH-1 trial study group 2023, ' First-in-human use of a modular capsid virus-like vaccine platform : An open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2 ', The Lancet Microbe, vol. 4, no. 3, pp. e140-e148 . https://doi.org/10.1016/S2666-5247(22)00337-8
The Lancet Microbe, 4, 3, pp. e140-e148
The Lancet Microbe, 4, e140-e148

Contains fulltext : 291067.pdf (Publisher’s version ) (Open Access) BACKGROUND: Capsid virus-like particles (cVLP) have proven safe and immunogenic and can be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP COV

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e14ac00b940c34782ba1e1c8bde5833a
https://curis.ku.dk/ws/files/340399546/1_s2.0_S2666524722003378_main.pdf